MRTX
$226.47
Mirati Therapeutics
($7.89)
(3.37%)
MRTX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($2.28)
Revenue:  $0.70 Mil
Wednesday
Feb 3
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRTX reports earnings?
Beat
Meet
Miss

Where is MRTX's stock price going from here?
Up
Flat
Down
Stock chart of MRTX
Analysts
Summary of analysts' recommendations for MRTX
Score
Grade
Pivots
Resistance
$240.42
$236.31
$231.39

$227.28

Support
$222.36
$218.25
$213.33
Tweet
Growth
Description
Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly